ArticleBMC pediatrics2026
Prolonged empirical antibiotic therapy despite negative blood cultures in neonates: a retrospective stewardship-oriented analysis.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpirical antibiotic therapy is routinely initiated in neonatal units for suspected sepsis; however, continuation of treatment despite negative blood cultures represents a major antimicrobial stewardship challenge. Prolonged exposure in early life may increase the risk of adverse outcomes and antimicrobial resistance.
objectivesTo evaluate the prevalence and independent predictors of prolonged empirical antibiotic therapy in neonates with negative blood cultures over a three-year period.
methodsThis retrospective cohort study included 550 neonates treated with empirical antibiotics between January 2023 and January 2026. Clinical data, laboratory parameters (C-reactive protein, white blood cell count, procalcitonin), gestational age, birth weight, indication for therapy, blood culture results, and antibiotic regimens classified according to the WHO AWaRe framework were analyzed. Prolonged therapy was defined as antibiotic treatment exceeding five days despite negative cultures. Days of therapy (DOT) and DOT per 1000 patient-days were calculated. Multivariable logistic regression identified independent predictors.
resultsBlood cultures were negative in 82.4% of neonates. Among these, 41.8% received antibiotics for more than five days. The mean duration of therapy was 6.7 ± 2.4 days, and DOT reached 724 per 1000 patient-days. Prematurity (< 37 weeks) was independently associated with prolonged therapy (OR 2.36; 95% CI 1.58-3.52; p < 0.001), particularly < 32 weeks (OR 3.41; 95% CI 2.01-5.79; p < 0.001). Birth weight < 1500 g (OR 2.87; 95% CI 1.74-4.72; p < 0.001), elevated CRP (> 20 mg/L) (OR 1.94; 95% CI 1.29-2.91; p = 0.002), and mechanical ventilation (OR 2.11; 95% CI 1.32-3.37; p = 0.001) were significant predictors. "Watch" antibiotics accounted for 38.6% of initial regimens.
conclusionsProlonged empirical antibiotic therapy despite negative blood cultures remains frequent in neonatal practice and is independently associated with prematurity, very low birth weight, inflammatory markers, and clinical severity. Targeted antimicrobial stewardship interventions are warranted to optimize neonatal antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.